Forbes October 27, 2023
Peter Ubel

Latuda is a drug to treat schizophrenia. It costs about $4,000 per month in the U.S. In Canada, the price is closer to $500.

Ibrance, a breast cancer drug, costs $10,000 more per month in the U.S. than in Canada.

Why these enormous price differences? For an answer to that question, consider another cancer. It is called metastatic cholangiocarcinoma. You probably know what the metastatic and the carcinoma parts of these words mean—that the cancer has spread beyond its origin. The “cholangio” part signifies the original location of the tumor: in the bile ducts, the slender tubes connecting your liver to your gallbladder and small intestine.

For people with distant metastases, when the cancer has spread far away from the...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, FDA, Govt Agencies, Healthcare System, Pharma, Pharma / Biotech, Pricing / Spending
The Download: speaking to robots, and growing pharmaceutical mushrooms
Sofinnova closes new fund and backs a trio of new biotechs
AstraZeneca's $1 Billion Deal Highlights Growing Interest in In Vivo Cell Therapies
Pharmacy Benefit Manager Reform Keeps Getting Scuttled, Despite Bipartisan Support
AI, patient data firms aim to speed up drug development

Share This Article